Akèy › Kansè (tout kalite) › Arizona
Etid klinik pou Kansè (tout kalite) nan Arizona
50 etid pou Kansè (tout kalite) ap chèche patisipan nan sit nan Arizona.
Vil nan Arizona
Tèks ofisyèl etid la (Anglè)
Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
- Mayo Clinic in Arizona, Scottsdale
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06880861Registry Study for Radiation Therapy Outcomes
- Mayo Clinic, Scottsdale
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 29, 2026 · NCT01255748Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- HonorHealth Scottsdale Osborn Medical Center, Scottsdale
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07195591Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Banner Health, Gilbert
- Mayo Clinic Hospital, Phoenix
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04981119A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- Mayo Clinic Hospital, Phoenix
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06989437A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
- City Of Hope - Phoenix /ID# 281323, Goodyear
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07365241TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America-Phoenix, Phoenix
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Banner MD Anderson Cancer Center, Gilbert
- Mayo Clinic Phoenix, Phoenix
Ap rekriteFaz 2/3
Tout laj · Tout sèks · Mizajou Sep 18, 2026 · NCT03435796RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- University of Arizona, Tucson
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07002034(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Mayo Clinic Arizona, Phoenix
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT04996875A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
- Mayo Clinic Phoenix, Phoenix
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT06634589A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Banner MD Anderson Cancer Center, Gilbert
- Banner University Medical Center Phoenix, Phoenix
- The University of Arizona Cancer Center - North Campus, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT06119581Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- Ironwood Cancer and Research Centers Scottsdale, Chandler
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06252649Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic, Phoenix
- University of Arizona-Cancer Center, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06072612ORB-021 In Patients With Advanced Solid Tumors
- Honor Health Clinical Research, Scottsdale
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT06607939A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
- Mayo Clinic Arizona, Phoenix
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07321106Project: Every Child for Younger Patients With Cancer
- Kingman Regional Medical Center, Kingman
- Banner Children's at Desert, Mesa
- Phoenix Childrens Hospital, Phoenix
- ak 1 plis
Ap rekriteEtid obsèvasyon
Jiska laj 25 · Tout sèks · Mizajou Aug 25, 2026 · NCT02402244Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
- East Valley Urology Center of Arizona, Queen Creek
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT07480356FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Mayo Clinic, Phoenix
- Honor Health, Scottsdale
- Arizona Cancer Center at University of Arizona, Tucson
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05919264A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
- Phoenix Children's Hospital, Phoenix
- Phoenix Children's Hospital, Phoenix
Ap rekriteFaz 2
Laj 1 a 39 · Tout sèks · Mizajou Aug 7, 2026 · NCT05999994Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Cancer Center at Saint Joseph's, Phoenix
- Mayo Clinic Hospital in Arizona, Phoenix
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT06580314Symptom Management and Survivorship Plus Coaching for Advanced Cancer Survivors and Their Caregivers
- University of Arizona Cancer Center, Tucson
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 20, 2026 · NCT07415564A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Mayo Clinic Arizona /ID# 251405, Phoenix
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT05650632Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Banner MD Anderson Cancer Center, Gilbert
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 30, 2026 · NCT06162221Molecular Genetics Studies of Cancer Patients and Their Relatives
- Valleywise Comprehensive Health Center - Phoenix, Phoenix
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Jun 29, 2026 · NCT04185935Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
- University of Arizona Cancer Center, Tucson
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 18, 2026 · NCT07407582Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- Southern Arizona VA Health Care System, Tucson, AZ, Tucson
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou Jun 17, 2026 · NCT05486572A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- Banner Health, Gilbert
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jun 12, 2026 · NCT06051695A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- Ironwood Cancer and Research Centers - Chandler II /ID# 275443, Chandler
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Jun 8, 2026 · NCT07005102Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- University of Arizona Cancer Center - Tucson /ID# 262698, Tucson
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT04777994Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
- Pioneer Research Center, LLC, Bullhead City
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT06463665I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
- Mayo Clinic - Scottsdale, Scottsdale
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 6, 2026 · NCT01042379A Nutrition & Exercise Prehabilitation Intervention on Inflammatory Biomarkers in AI Cancer Patients
- University of Arizona Cancer Center, Tucson
Ap rekrite
Laj 18 a 80 · Tout sèks · Mizajou Apr 30, 2026 · NCT06644560CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- St. Joseph's Hospital and Medical Center, Phoenix
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT03328078Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
- Honor Health, Scottsdale
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 16, 2026 · NCT06959706INTERogating Cancer for Etiology, Prevention and Therapy Navigation
- Mayo Clinic in Arizona, Scottsdale
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 7, 2026 · NCT06008392Multi-Cancer Detection Observational Cohort Study
- Mayo Clinic in Arizona, Scottsdale
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 21 ak plis · Tout sèks · Mizajou Apr 6, 2026 · NCT06962995Arizona Cancer Center Biospecimen Repository
- Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Apr 6, 2026 · NCT00896935Caris Biorepository Research Protocol
- Southwest Medical Imaging, Scottsdale
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Jan 21, 2026 · NCT01499394Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
- Honor Health Research Institute, Scottsdale
- University of Arizona, Tucson
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Dec 19, 2025 · NCT05270213Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.